Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2496-2502

  Lin, Lan ^a   Lee, Jeannette Y ^a   Kaplan, Lawrence D ^a   Dezube, Bruce J ^a   Noy, Ariela ^a   Krown, Susan E ^a   Levine, Alexandra M ^a   Yu, Yanxing ^a   Hayward, Gary S ^a   Ambinder, Richard F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DNA DETERMINATION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL DESTRUCTION; VIREMIA; B CELL LYMPHOMA; BLOOD; CLINICAL TRIAL; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, KAPOSI;

EID: 66349125602     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1707     Document Type: Article

References (39)

1. Moore PS: The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). N Engl J Med 343:1411-1413, 2000 (Pubitemid 30826046)
2. Boshoff C, Schulz TF, Kennedy MM, et al: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1:1274-1278, 1995
3. Li JJ, Huang YQ, Cockerell CJ, et al: Localization of human herpes-like virus type 8 in vascular endothelial cells and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ hybridization. Am J Pathol 148:1741-1748, 1996
4. Orenstein JM, Alkan S, Blauvelt A, et al: Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS 11:F35-F45, 1997 (Pubitemid 27135875)
5. Blasig C, Zietz C, Haar B, et al: Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol 71:7963-7968, 1997 (Pubitemid 27391749)
6. Cannon JS, Nicholas J, Orenstein JM, et al: Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis 180:824-828, 1999 (Pubitemid 29411370)
7. Chiou CJ, Poole LJ, Kim PS, et al: Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J Virol 76:3421-3439, 2002
8. Harrington WJ Jr, Bagasra O, Sosa CE, et al: Human herpesvirus type 8 DNA sequences in cellfree plasma and mononuclear cells of Kaposi's sarcoma patients. J Infect Dis 174:1101-1105, 1996 (Pubitemid 26357477)
9. Whitby D, Howard MR, Tenant-Flowers M, et al: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346: 799-802, 1995
10. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-1543, 2005
11. Noy A, Scadden DT, Lee J, et al: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-998, 2005 (Pubitemid 46205948)
12. Cianfrocca M, Cooley TP, Lee JY, et al: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. J Clin Oncol 20:153-159, 2002 (Pubitemid 34032606)
13. Cannon JS, Ciufo D, Hawkins AL, et al: A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol 74:10187-10193, 2000 (Pubitemid 30780827)
14. Jahr S, Hentze H, Englisch S, et al: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-1665, 2001 (Pubitemid 34292602)
15. Chan KC, Zhang J, Chan AT, et al: Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63:2028-2032, 2003 (Pubitemid 36538602)
16. Campbell TB, Borok M, White IE, et al: Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe. Clin Infect Dis 36:1144-1151, 2003 (Pubitemid 36549635)
17. Johnson PJ, Lo YM: Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 48:1186-1193, 2002
18. Jiang WW, Zahurak M, Goldenberg D, et al: Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 119:2673-2676, 2006 (Pubitemid 44691324)
19. Dulaimi E, Hillinck J, Ibanez de Caceres I, et al: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10:6189-6193, 2004 (Pubitemid 39287525)
20. Ryan JL, Fan H, Swinnen LJ, et al: Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 13:61-68, 2004 (Pubitemid 38668140)
21. Chan AT, Lo YM, Zee B, et al: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619, 2002 (Pubitemid 35378726)
22. Leung SF, Zee B, Ma BB, et al: Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24:5414-5418, 2006 (Pubitemid 46623174)
23. Krown SE, Lee JY, Lin L, et al: Interferonalpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: An AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 41:149-153, 2006
24. Laney AS, Cannon MJ, Jaffe HW, et al: Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS 21:1541-1545, 2007
25. Marcelin AG, Motol J, Guihot A, et al: Relationship between the quantity of Kaposi sarcomaassociated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis 196:1163-1166, 2007 (Pubitemid 47580271)
26. Nsubuga MM, Biggar RJ, Combs S, et al: Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions. Cancer Lett 263: 182-188, 2008
27. Humphrey RW, O'Brien TR, Newcomb FM, et al: Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: Association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood 88: 297-301, 1996
28. Little RF, Merced-Galindez F, Staskus K, et al: A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 187:149-153, 2003 (Pubitemid 36034485)
29. Casper C, Krantz EM, Corey L, et al: Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 198:23-30, 2008 (Pubitemid 351920285)
30. Bourboulia D, Aldam D, Lagos D, et al: Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18:485-493, 2004 (Pubitemid 38365876)
31. Campbell TB, Staskus KA, Folkvord J, et al: Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases. J Infect Dis 191:367-371, 2005 (Pubitemid 40139761)
32. Yang J, Tao Q, Flinn IW, et al: Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 96:4055-4063, 2000
33. Powles T, Stebbing J, Montoto S, et al: Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 110:4132-4133, 2007 (Pubitemid 350248476)
34. Bower M, Stebbing J, Tuthill M, et al: Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 111:3986-3990, 2008
35. Bower M, Powles T, Williams S, et al: Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147: 836-839, 2007 (Pubitemid 351664423)
36. Casquero A, Barroso A, Fernandez Guerrero ML, et al: Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 85:185-187, 2006 (Pubitemid 43174275)
37. Gerard L, Berezne A, Galicier L, et al: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350-3356, 2007 (Pubitemid 47325622)
38. Pantanowitz L, Fruh K, Marconi S, et al: pathology of rituximab-induced kaposi sarcoma flare. BMC Clin Pathol 8:7, 2008
39. Clifford KS, Demierre MF: Progression of classic Kaposi's sarcoma with rituximab. J Am Acad Dermatol 53:155-157, 2005 (Pubitemid 40826715)